Latest News On Texas

Latest California Healthline Stories

KFF Health News' 'What the Health?': Biden Budget Touches All the Bases

Very little in the proposed budget released by the Biden administration is likely to become law, particularly with Republicans in charge of the U.S. House. Still, the document is an important statement of the president’s policy priorities, and it’s clear health programs are among those he feels are important. Meanwhile, five women who were denied abortions when their pregnancies threatened their lives are suing Texas. Shefali Luthra of The 19th, Victoria Knight of Axios, and Margot Sanger-Katz of The New York Times join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Harris Meyer, who reported and wrote the two latest KHN-NPR “Bill of the Month” features. Both were about families facing unexpected bills following childbirth.

Adolescentes en Texas podían obtener control de la natalidad en clínicas federales, hasta que un padre cristiano lo objetó

Una sorprendente decisión judicial emitida en diciembre, un juez federal dictaminó que estas clínicas violan la ley estatal de Texas y los derechos constitucionales federales, cortando de raíz una fuente vital de atención médica para mujeres jóvenes en el estado.

Hospitales rurales aplican a nuevo programa federal para intentar sobrevivir

Más de 140 hospitales rurales han cerrado en todo el país desde 2010, y observadores de políticas de salud no están seguros de cuántas de las más de 1,700 instalaciones rurales elegibles para la nueva designación aplicarán a un nuevo programa.

KFF Health News' 'What the Health?': March Medicaid Madness

With Medicare and Social Security apparently off the table for federal budget cuts, the focus has turned to Medicaid, the federal-state health program for those with low incomes. President Joe Biden has made it clear he wants to protect the program, along with the Affordable Care Act, but Republicans will likely propose cuts to both […]

One Texas Judge Will Decide Fate of Abortion Pill Used by Millions of American Women

“What happens in Texas doesn’t stay in Texas,” warns an abortion rights advocate bracing for a district judge’s ruling on whether the abortion pill mifepristone was properly authorized by the FDA. His decision could force the medication off the U.S. market.

KHN’s ‘What the Health?’: Health Spending? Only Congress Knows

Top negotiators in Congress have agreed to a framework for government spending into next year, but there are details to iron out before a vote — such as the scheduled Medicare payment cuts that have providers worried. Also, the Biden administration reopens its program allowing Americans to request free covid-19 home tests, as hopes for pandemic preparedness measures from Congress dim. Rachel Cohrs of Stat, Alice Miranda Ollstein of Politico, and Rebecca Adams of KHN join KHN’s Mary Agnes Carey to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.

Empresas de capital riesgo invierten en el negocio de los ensayos clínicos de medicamentos. ¿Cuál es el riesgo para los pacientes?

Para lanzar un nuevo fármaco al mercado, la Administración de Alimentos y Medicamentos (FDA) exige a las farmacéuticas estudios exhaustivos para demostrar su seguridad y eficacia. Conseguir que un medicamento salga al mercado unos meses antes, y con menos gastos de lo habitual, puede traducirse en beneficios millonarios para el fabricante.